Tipsheet: American Transplant Congress 2023
Prominent Investigators to Present New Research on Living Donor Organ Donation, Protocols to Prevent Organ Rejection
Cedars-Sinai clinicians and scientists, including Medawar Prize winner Stanley Jordan, MD, and prominent nephrology and immunology investigator Peter Heeger, MD, will share their latest advances in research at the American Transplant Congress (ATC), June 3-7, 2023, in San Diego. The ATC is the joint annual meeting of the American Society of Transplant Surgeons and the American Society of Transplantation.
Cedars-Sinai physicians and scientists will be available for interviews on a variety of clinical and research topics related to transplantation and immunology.
Highlights of this year’s ATC include presentations about removing disincentives to living donor kidney donation, an assay that the Cedars-Sinai transplant immunology team developed to identify patients at risk for antibody-mediated rejection, and desensitization protocols for highly HLA-sensitized patients, a field in which Cedars-Sinai is a world leader.
For more information about any of the below presentations, or to schedule an interview with one of the Cedars-Sinai transplant experts, please contact Sarah Lichtman at 540-834-7954 or sarah.lichtman@cshs.org.
Sunday, June 4
Oral Presentation: IMPACT—Pursuing Healthy Weight for Life: Integrating Long-Term Weight Management to Promote Wellness and Sustained Weight Loss Among Overweight and/or Obese Living Donor Candidates
7–8 a.m.
Ellen Shukhman, RN
Oral Presentation: Daratumumab (Anti-CD38) for Desensitization (Des) of Treatment-Resistant Highly HLA-Sensitized ESRD Patients
3:50–4 p.m.
Ashley Vo, PharmD
Oral Presentation: Assessment of NK Cell Alloreactivity in HLA-Sensitized Patients: Association With Risk for Antibody-Mediated Rejection
5:10–5:20 p.m.
Ashley Vo, PharmD
Edmund Huang, MD
Monday, June 5
Oral Presentation: IMPACT—Complement System in Organ Transplantation
7–8 a.m.
Peter Heeger, MD
Oral Presentation: Meet the Expert—The Time Is Now: Removing Disincentives to Living Donation
12:15–12:30 p.m.
Ellen Shukhman, RN
Oral Presentation: Assessing the Safety & Efficacy of Renal Artery Infusions of C1 Esterase Inhibitor (C1INH) in Kidney Transplant Recipients at Risk for IRI/DGF
3:30–3:40 p.m.
Noriko Ammerman, PharmD
Oral Presentation: Clazakizumab (Anti-IL6 Monoclonal) to Reduce Donor-Specific HLA Antibodies (DSA) and Improve Outcomes in Post-Kidney-Transplant Patients With Chronic Active Antibody-Mediated Rejection (NCT03380377)
4–5 p.m.
Stanley Jordan, MD
Tuesday, June 6
Oral Presentation: A Randomized Phase II Study of MAU868 vs. Placebo for BK Viremia in Kidney Transplant Recipients: BK Viral Kinetics and Outcomes in Two Dosing Cohorts
5:10–5:20 p.m.
Stanley Jordan, MD
Rapid Fire Oral Abstract Session: Multicenter Experience Using Donor-Derived Cell-Free DNA in Pediatric Patients Less Than 20 Kg
4:50 p.m.
Dechu Puliyanda, MD